Mucovit (Acetylcysteine)

Acetylcysteine, the active ingredient in Mucovit, is a mucolytic agent presented as an oral dosage form for oral use. It helps to thin and loosen thick mucus in the respiratory tract of patients with acute or chronic bronchitis and related conditions.

GNH USA supplies Mucovit as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Acetylcysteine is used as a mucolytic in respiratory disorders characterized by thickened secretions.

Acute bronchitis: reduces mucus viscosity to improve cough clearance. Chronic bronchitis: facilitates expectoration and eases airway obstruction. Chronic obstructive pulmonary disease (COPD): helps maintain airway patency by thinning secretions.

Acetylcysteine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Abdominal discomfort - Altered taste sensation - Skin rash

Serious or Rare Side Effects: - Anaphylactic reaction - Severe skin eruptions such as Stevens‑Johnson syndrome - Bronchospasm, especially in asthmatic patients - Hepatic dysfunction - Neutropenia or other blood dyscrasias - Angioedema

Before initiating therapy with acetylcysteine, clinicians should consider several safety aspects.

Assess renal function: dose may need adjustment in severe impairment. Monitor for bronchospasm: observe patients with a history of asthma. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Use cautiously in hepatic disease: monitor liver enzymes. Inform patients about possible gastrointestinal upset and advise taking with food if tolerated. Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Acetylcysteine can influence the activity of several concomitant medicines.

Major Interactions (Avoid): - Nitroprusside: concurrent use may potentiate hypotensive effects. - Activated charcoal: may reduce acetylcysteine absorption if given within 2 hours. - Anticoagulants (e.g., warfarin): increased risk of bleeding.

Moderate Interactions (Monitor Closely): - Penicillins and carbapenems: possible reduction in antibacterial efficacy. - Inhaled bronchodilators: additive cough suppression may occur. - Diuretics: monitor electrolyte balance as acetylcysteine can affect potassium levels.